Drugs / Volagidemab
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05093517 | Nov 2021 → Mar 2022 | glucose intolerance, type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT07212868 | Feb 2026 → May 2030 expected | — | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 1 | NCT06272695 | Feb 2024 → Feb 2025 | type 1 diabetes mellitus | REMD Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04330625 | Nov 2020 → May 2021 | hyperglycemia | Duke University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04253223 | Apr 2020 → May 2021 | hyperglycemia | Duke University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02715193 | Mar 2016 → Jan 2017 | type 1 diabetes mellitus | REMD Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03919617 | Jul 2019 → Jul 2021 | type 1 diabetes mellitus | University of California, San Diego | Completed | No outcome recorded |
| Phase 1/2 | NCT02455011 | Sep 2015 → Jan 2018 | type 2 diabetes mellitus | REMD Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04779645 | Jul 2021 → Jul 2024 overdue | type 1 diabetes mellitus | University of California, San Diego | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03117998 | Sep 2017 → Mar 2021 | type 1 diabetes mellitus | REMD Biotherapeutics, Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT05696366 Comparator | Sep 2024 → Jan 2028 expected | type 1 diabetes mellitus | University of California, San Diego | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04545411 Comparator | Feb 2021 → Feb 2022 | type 1 diabetes mellitus | University of California, San Diego | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Volagidemab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06272695 ↗ |
| Known as | AMG 477 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298213 ↗ |
| Known as | REMD 477 | “before and 12 weeks after treatment with REMD 477 or placebo.” NCT05093517 ↗11“We use an investigational drug called REMD 477.” NCT07212868 ↗ |
| Action | Inhibit | “a glucagon receptor antagonist” PMID 29283470 ↗ Jan 2018 |
| Modality | Monoclonal antibody | “human monoclonal antibody” NCT05696366 ↗ |
| Route | Subcutaneous | “repeated SC doses” NCT02455011 ↗ |
| Target | GCGR | “blocking glucagon receptor (GCGR) signaling” NCT04330625 ↗ |